FI119359B - Lymfotoxin-alfa/beta-komplex och antilymfotoxin-beta-reseptorantikroppar som antitumörmedel - Google Patents
Lymfotoxin-alfa/beta-komplex och antilymfotoxin-beta-reseptorantikroppar som antitumörmedel Download PDFInfo
- Publication number
- FI119359B FI119359B FI973118A FI973118A FI119359B FI 119359 B FI119359 B FI 119359B FI 973118 A FI973118 A FI 973118A FI 973118 A FI973118 A FI 973118A FI 119359 B FI119359 B FI 119359B
- Authority
- FI
- Finland
- Prior art keywords
- ifn
- cells
- complexes
- mab
- indications
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (9)
1. En farmaceutisk komposition, som bestär av ät-minstone ett LT-p-R aktiverande ämne, kännetecknad av 5 att ett LT-p-R aktiverande ämne bestär av en anti-LT-p-R -antikropp.
2. Användning av ätminstone ett LT-p-R aktiverande ämne för framställning av en farmaceutisk komposition för behandling eller minskning av framskridningen, svärigheten 10 eller effekterna av neoplasi, kännetecknad av att ett LT-p-R aktiverande ämne bestär av en anti-LT-p-R -antikropp .
3. Användning av ett LT-α/ρ heteromeriskt komplex för framställning av en farmaceutisk komposition, som är 15 planerad att användas i närvaro av ätminstone ett LT-p-R aktiverande ämne för behandling eller minskning av framskridningen, svärigheten eller effekterna av neoplasi.
4. Användning enligt patentkrav 3, kännetecknad av att ett LT-p-R aktiverande ämne bestär av en LT-p-R 20 -antikropp och/eller IFN-γ.
.. 5. Användning av tvärbundna anti-LT-p-R -anti- • · · ‘ *. kroppar som ett första LT-p-R aktiverande ämne för fram- ' ställning av en farmaceutisk komposition, som är planerad ‘ * att användas i närvaro av ett andra LT-p-R aktiverande äm- • · · • *,· 25 ne för behandling eller minskning av framskridningen, svä- ·· • *·· righeten eller effekterna av neoplasi. :T:
6. Användning enligt patentkrav 5, känneteck nad av att det andra LT-p-R aktiverande ämnet bestär av IFN-γ. • · • · .···. 30
7. Ett förfarande för selektion av ett LT-p-R ak- ♦ ♦ *·’ tiverande ämne som fungerar i närvaro av LT-α/ρ heteromera : ** komplex, varvid förfarande bestär av stegen: • · · ·...· a) odling av cellerna i närvaro av LT-α/ρ hetero- ♦ mera komplex, ett första LT-p-R aktiverande ämne och ett • * · • · ,·, : 35 andra förmodat LT-p-R aktiverande ämne; och • *i • · 119359 77 b) bestämning av ifall det andra förmodade LT-p-R aktiverande ämnet ökar anti-tumor aktiviteten av LT-α/β heteromera komplexet i närvaro av det första LT-p-R aktiverande ämnet.
8. En farmaceutisk komposition som bestär av en LT-p-R -antikropp.
9. Användning av en anti-LT-3-R antikropp för framställning av en farmaceutisk komposition för behand-ling eller minskning av framskridningen, svärigheten eller 10 effekterna av neoplasi. • · • * φ • · · • · • φ m ® · • · · • · · • Φ • · • Φ • Φ • Φ® • Φ ®Φ • Φ · • * · • · • Φ · Φ Φ Φ Φ · Φ·Φ • ® Φ · • •Φ Φ ΦΦ Φ Φ φ φ # Φ ΦΦφ φ Φ Φ Φ ΦΦΦ φ Φ Φ ΦΦΦ ΦΦΦ Φ φ Φ Φ ΦΦΦ φ ΦΦ Φ φ
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37896895A | 1995-01-26 | 1995-01-26 | |
| US37896895 | 1995-01-26 | ||
| PCT/US1996/001386 WO1996022788A1 (en) | 1995-01-26 | 1996-01-26 | LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS |
| US9601386 | 1996-01-26 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI973118A0 FI973118A0 (sv) | 1997-07-25 |
| FI973118A FI973118A (sv) | 1997-09-25 |
| FI119359B true FI119359B (sv) | 2008-10-31 |
Family
ID=23495285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI973118A FI119359B (sv) | 1995-01-26 | 1997-07-25 | Lymfotoxin-alfa/beta-komplex och antilymfotoxin-beta-reseptorantikroppar som antitumörmedel |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP1407781A1 (sv) |
| JP (2) | JPH10513161A (sv) |
| KR (2) | KR100475492B1 (sv) |
| CN (3) | CN1589902A (sv) |
| AT (1) | ATE268604T1 (sv) |
| AU (1) | AU725351B2 (sv) |
| BG (1) | BG62599B1 (sv) |
| BR (1) | BR9606808A (sv) |
| CA (1) | CA2211443A1 (sv) |
| CZ (1) | CZ298711B6 (sv) |
| DE (1) | DE69632681T2 (sv) |
| DK (1) | DK0809510T3 (sv) |
| EA (1) | EA000096B1 (sv) |
| EE (1) | EE04453B1 (sv) |
| ES (1) | ES2220972T3 (sv) |
| FI (1) | FI119359B (sv) |
| HK (1) | HK1006356A1 (sv) |
| HU (1) | HUP9801746A3 (sv) |
| NO (1) | NO322744B1 (sv) |
| NZ (1) | NZ303405A (sv) |
| PL (1) | PL185364B1 (sv) |
| PT (1) | PT809510E (sv) |
| RO (1) | RO118634B1 (sv) |
| SK (1) | SK286497B6 (sv) |
| WO (1) | WO1996022788A1 (sv) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| US6140467A (en) * | 1997-07-07 | 2000-10-31 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
| US7118742B2 (en) | 1997-07-07 | 2006-10-10 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
| US7060667B1 (en) | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
| EP1119370B1 (en) | 1998-10-09 | 2006-06-14 | Biogen Idec MA Inc. | Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway |
| TR200602095T2 (tr) * | 2000-10-13 | 2007-02-21 | Biogen Idec Ma Inc. | Hümanize Anti-LT-Beta-R antikorları |
| AU2003248782A1 (en) * | 2002-07-01 | 2004-01-19 | Biogen Idec Ma Inc. | Humanized anti-lymphotoxin beta receptor antibodies |
| RS20050481A (en) * | 2002-12-20 | 2007-08-03 | Biogen Idec Ma Inc., | Lymphotoxin beta receptor agents in combination with chemotherapeutic agents |
| JP2006515750A (ja) * | 2002-12-20 | 2006-06-08 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 多価リンホトキシンβレセプターアゴニストおよびそれを使用する治療 |
| JP5091476B2 (ja) | 2003-06-27 | 2012-12-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用 |
| CN1980957A (zh) | 2004-03-23 | 2007-06-13 | 比奥根艾迪克Ma公司 | 受体偶联剂及其治疗用途 |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| EP1764371A1 (de) * | 2005-04-25 | 2007-03-21 | Xantos Biomedicine AG | Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie |
| CN101073665B (zh) * | 2006-05-17 | 2014-11-26 | 上海复旦张江生物医药股份有限公司 | 淋巴毒素在制备增加化疗药物敏感性的药物中的应用 |
| US20120282245A1 (en) | 2006-10-03 | 2012-11-08 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
| CN101653599A (zh) | 2006-10-20 | 2010-02-24 | 比奥根艾迪克Ma公司 | 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗 |
| US8338376B2 (en) | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
| WO2010039714A1 (en) * | 2008-09-30 | 2010-04-08 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to lymphotoxin antagonists |
| IN2014CN04961A (sv) * | 2011-12-05 | 2015-09-18 | Igenica Biotherapeutics Inc | |
| AU2016209324B2 (en) | 2015-01-20 | 2020-02-27 | Igm Biosciences, Inc. | Tumor necrosis factor (TNF) superfamily receptor binding molecules and uses thereof |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| EP4255929A2 (en) | 2020-12-02 | 2023-10-11 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| WO2023198848A1 (en) | 2022-04-13 | 2023-10-19 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6124599A (ja) * | 1984-07-11 | 1986-02-03 | Kyowa Hakko Kogyo Co Ltd | 新規ヒトインタ−フエロン−ｒポリペプチド誘導体 |
| JPS61277628A (ja) * | 1985-06-04 | 1986-12-08 | Asahi Chem Ind Co Ltd | 癌治療用白血球刺激材 |
| US4770995A (en) * | 1985-08-29 | 1988-09-13 | New York Blood Center, Inc | Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin |
| WO1994013808A2 (en) * | 1992-12-04 | 1994-06-23 | Biogen, Inc. | LYMPHOTOXIN-β, LYMPHOTOXIN-β COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF |
| DE69132629T2 (de) * | 1990-06-27 | 2002-04-18 | Biogen, Inc. | Oberflächenkomplexbildung von lymphotoxin |
-
1996
- 1996-01-26 AU AU49704/96A patent/AU725351B2/en not_active Ceased
- 1996-01-26 CN CNA2004100070585A patent/CN1589902A/zh active Pending
- 1996-01-26 NZ NZ303405A patent/NZ303405A/en not_active IP Right Cessation
- 1996-01-26 BR BR9606808A patent/BR9606808A/pt not_active Application Discontinuation
- 1996-01-26 KR KR10-2004-7015796A patent/KR100475492B1/ko not_active IP Right Cessation
- 1996-01-26 DK DK96906260T patent/DK0809510T3/da active
- 1996-01-26 EP EP20030022584 patent/EP1407781A1/en not_active Withdrawn
- 1996-01-26 CN CNA2006101007130A patent/CN1900116A/zh active Pending
- 1996-01-26 PL PL96321758A patent/PL185364B1/pl unknown
- 1996-01-26 DE DE69632681T patent/DE69632681T2/de not_active Expired - Fee Related
- 1996-01-26 EE EE9700255A patent/EE04453B1/xx not_active IP Right Cessation
- 1996-01-26 SK SK986-97A patent/SK286497B6/sk not_active IP Right Cessation
- 1996-01-26 JP JP8523078A patent/JPH10513161A/ja not_active Withdrawn
- 1996-01-26 WO PCT/US1996/001386 patent/WO1996022788A1/en active IP Right Grant
- 1996-01-26 PT PT96906260T patent/PT809510E/pt unknown
- 1996-01-26 CN CNB961922710A patent/CN1146442C/zh not_active Expired - Fee Related
- 1996-01-26 EA EA199700144A patent/EA000096B1/ru not_active IP Right Cessation
- 1996-01-26 AT AT96906260T patent/ATE268604T1/de not_active IP Right Cessation
- 1996-01-26 CA CA002211443A patent/CA2211443A1/en not_active Abandoned
- 1996-01-26 ES ES96906260T patent/ES2220972T3/es not_active Expired - Lifetime
- 1996-01-26 CZ CZ0236197A patent/CZ298711B6/cs not_active IP Right Cessation
- 1996-01-26 HU HU9801746A patent/HUP9801746A3/hu unknown
- 1996-01-26 EP EP96906260A patent/EP0809510B1/en not_active Expired - Lifetime
- 1996-01-26 KR KR1019970705213A patent/KR100470739B1/ko not_active IP Right Cessation
- 1996-01-26 RO RO97-01398A patent/RO118634B1/ro unknown
-
1997
- 1997-07-22 NO NO19973385A patent/NO322744B1/no not_active IP Right Cessation
- 1997-07-25 FI FI973118A patent/FI119359B/sv active IP Right Grant
- 1997-08-26 BG BG101855A patent/BG62599B1/bg unknown
-
1998
- 1998-06-02 HK HK98104772A patent/HK1006356A1/xx not_active IP Right Cessation
-
2007
- 2007-03-12 JP JP2007062695A patent/JP2007169296A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI119359B (sv) | Lymfotoxin-alfa/beta-komplex och antilymfotoxin-beta-reseptorantikroppar som antitumörmedel | |
| US7459537B2 (en) | Anti-lymphotoxin-β receptor antibodies as anti-tumor agents | |
| Browning et al. | Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. | |
| KR101004174B1 (ko) | 세포소멸을 유도하는 시토킨 | |
| US6284236B1 (en) | Cytokine that induces apoptosis | |
| US20030059427A1 (en) | Isolation and characterization of highly active anti-CD40 antibody | |
| CA2179196A1 (en) | Method of preventing or treating disease characterized by neoplastic cells expressing cd40 | |
| US6015559A (en) | Fas antagonists | |
| KR20010080073A (ko) | 림포독소 베타 경로의 차단에 의한 바이러스-유도성 전신쇼크 및 호흡 장애의 반전 | |
| EP0689600B1 (en) | Process to induce the death of tumor cells | |
| MXPA97005629A (en) | Linfotoxin-alpha / beta complexes and anti-tetration antibodies of lymphotoxin beta as agents anti-tu | |
| Browning | Signaling through the Lymphotoxin 13 Receptor Induces the Death of Some Adenocarcinoma Tumor Lines By Jeffrey L. Browning, Konrad Miatkowski, Irene Sizing, David Griffiths, Mohammad Zafari, Christopher D. Benjamin, Werner Meier, and Fabienne Mackay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer of assignment of patent |
Owner name: BIOGEN IDEC MA INC. Free format text: BIOGEN IDEC MA INC. |
|
| FG | Patent granted |
Ref document number: 119359 Country of ref document: FI |